Research programme: lung disease therapeutics - PharmaMaxAlternative Names: RES-001; RES-100; RES-110; RES-200; RES-300; RES-600; RES-800; RES-900
Latest Information Update: 22 Jan 2016
At a glance
- Originator PharmaMax
- Mechanism of Action Beta-adrenergic receptor agonists; Inflammation mediator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease; Cough; Lung cancer; Pulmonary fibrosis
Most Recent Events
- 22 Jan 2016 Preclinical trials in Chronic obstructive pulmonary disease in China (Inhalation)